HER2 as a treatment target in desmoplastic small round cell tumors (DSRCT): a retrospective study in a certified sarcoma center

PURPOSE: Desmoplastic small round cell tumors (DSRCT) are exceptionally rare and aggressive sarcomas with limited therapeutic options and scarce clinical evidence. We aimed to characterize the clinical course and treatment of patients with molecularly confirmed DSRCT and to investigate HER2 expression as a potential therapeutic target, including real-world experience with trastuzumab deruxtecan (T-DXd). METHODS: We retrospectively analyzed patients with DSRCT treated at our specialized and certified sarcoma center. Diagnosis was confirmed by detection of the pathognomonic EWSR1::WT1 fusion. Clinical characteristics, treatment strategies, surgical outcomes, HER2 immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) results were assessed. Clinical outcomes of patients receiving T-DXd were reviewed. RESULTS: Eleven patients were identified (median age 22 years, range 5-63; 81.8% male). HER2 IHC was 0 in three patients (27.3%), 1 + in three (27.3%), and 2 + in five (45.5%); none showed 3 + expression, and all tumors were FISH-negative. Two extensively pretreated patients with HER2 IHC 2+/FISH-negative tumors received off-label treatment with T-DXd and demonstrated initial radiological responses. One patient experienced subsequent progression and died, whereas the second maintained disease control after more than 10 cycles despite chronic dialysis and without substantial additional toxicity. CONCLUSIONS: This molecularly confirmed cohort highlights the aggressive clinical course and substantial unmet therapeutic need in DSRCT. HER2 protein expression was observed in a considerable proportion of tumors despite the absence of HER2 amplification. Responses to T-DXd in two HER2 IHC 2+/FISH-negative patients provide a hypothesis-generating clinical signal supporting further investigation of HER2-directed antibody-drug conjugates in DSRCT.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-11-13
DOI
https://doi.org/10.1007/s00432-026-06668-6
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HER2 as a treatment target in desmoplastic small round cell tumors (DSRCT): a retrospective study in a certified sarcoma center

Robert Rottscholl, Ruth Ladurner, Christoph K.W. Deinzer, Lars Zender et al.
5 links
Journal of Cancer Research and Clinical Oncology
Sarcoma Diagnosis and Treatment
article

HER2 as a treatment target in desmoplastic small round cell tumors (DSRCT): a retrospective study in a certified sarcoma center

Robert Rottscholl, Ruth Ladurner, Christoph K.W. Deinzer, Lars Zender, Katrin Benzler, Jens Strohäker
article en

Abstract

PURPOSE: Desmoplastic small round cell tumors (DSRCT) are exceptionally rare and aggressive sarcomas with limited therapeutic options and scarce clinical evidence. We aimed to characterize the clinical course and treatment of patients with molecularly confirmed DSRCT and to investigate HER2 expression as a potential therapeutic target, including real-world experience with trastuzumab deruxtecan (T-DXd). METHODS: We retrospectively analyzed patients with DSRCT treated at our specialized and certified sarcoma center. Diagnosis was confirmed by detection of the pathognomonic EWSR1::WT1 fusion. Clinical characteristics, treatment strategies, surgical outcomes, HER2 immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) results were assessed. Clinical outcomes of patients receiving T-DXd were reviewed. RESULTS: Eleven patients were identified (median age 22 years, range 5-63; 81.8% male). HER2 IHC was 0 in three patients (27.3%), 1 + in three (27.3%), and 2 + in five (45.5%); none showed 3 + expression, and all tumors were FISH-negative. Two extensively pretreated patients with HER2 IHC 2+/FISH-negative tumors received off-label treatment with T-DXd and demonstrated initial radiological responses. One patient experienced subsequent progression and died, whereas the second maintained disease control after more than 10 cycles despite chronic dialysis and without substantial additional toxicity. CONCLUSIONS: This molecularly confirmed cohort highlights the aggressive clinical course and substantial unmet therapeutic need in DSRCT. HER2 protein expression was observed in a considerable proportion of tumors despite the absence of HER2 amplification. Responses to T-DXd in two HER2 IHC 2+/FISH-negative patients provide a hypothesis-generating clinical signal supporting further investigation of HER2-directed antibody-drug conjugates in DSRCT.

Journal of Cancer Research and Clinical OncologyVol. 152(11)
Universitätsklinikum Tübingen (DE)
Eberhard Karls Universität Tübingen, Universitätsklinikum Tübingen
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon